1.Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
Min Sung YOON ; Hee Seung LEE ; Chang Moo KANG ; Woo Jung LEE ; Jiyoung KEUM ; Min Je SUNG ; Seungseob KIM ; Mi‑Suk PARK ; Jung Hyun JO ; Moon Jae CHUNG ; Jeong Youp PARK ; Seung Woo PARK ; Si Young SONG ; Ho Kyoung HWANG ; Seungmin BANG
Gut and Liver 2022;16(1):118-128
Background/Aims:
Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC.
Methods:
We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC: 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 1:3 propensity score matching (PSM) was performed to reduce selection bias.
Results:
Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis.
Conclusions
We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies.
2.Ileal epithelioid leiomyosarcoma with omental and peritoneal seeding.
Chung Hyoun KIM ; Sun Young KIM ; Chang Kil JUNG ; Jung Pil CHOI ; Keum Soo SEO ; Jun Ho LEE ; Jae Hyung CHOI
Yeungnam University Journal of Medicine 2017;34(1):132-136
Leiomyosarcoma (LMS) of the small intestine is a rare tumor, accounting for about 1% of all malignant mesenchymal lesions in the gastrointestinal tract. Since small bowel tumors are initially asymptomatic and nonspecific, delayed diagnosis and treatment are common. We found that a 44-year-old male patient who came in for lower abdominal pain had partial obstruction in the small bowel. Multiple ascites and ileal tumors involving peritoneal seeding were observed from his abdominal computed tomography. He was diagnosed as epithelioid LMS involving peritoneal transition after surgical resection, and the outpatient department has planned for a conservative therapy with observation. To the best of our knowledge, ileal epithelioid LMS accompanying a huge omental mass, with a size of 18 cm in dimension, and peritoneal seeding has not yet been reported in Korea. We report this rare case with literature review.
Abdominal Pain
;
Adult
;
Ascites
;
Delayed Diagnosis
;
Gastrointestinal Tract
;
Humans
;
Ileum
;
Intestine, Small
;
Korea
;
Leiomyosarcoma*
;
Male
;
Outpatients
3.Ceruminous Pleomorphic Adenoma of the External Auditory Canal: Two Case Reports and Review of the Literature.
Juyong CHUNG ; Dam Ho LEE ; Keum Ha CHOI
Korean Journal of Otolaryngology - Head and Neck Surgery 2017;60(4):191-195
Ceruminous glands are specialized apocrine glands located in the external auditory canal (EAC). Pleomorphic adenoma (PA) of the EAC is derived from these ceruminous glands. Tumors arising from these ceruminous glands are rare. Furthermore, ceruminous PA of the EAC is extremely rare. About 35 cases have been reported to date in the English literature, and only 4 cases have been reported in Korea. There are several controversial issues about these rare tumors such as nomenclature, histogenesis and classification. We report here on two cases of ceruminous PA and review the cases in the Korean literature.
Adenoma
;
Adenoma, Pleomorphic*
;
Apocrine Glands
;
Classification
;
Ear Canal*
;
Korea
4.Ileal epithelioid leiomyosarcoma with omental and peritoneal seeding
Chung Hyoun KIM ; Sun Young KIM ; Chang Kil JUNG ; Jung Pil CHOI ; Keum Soo SEO ; Jun Ho LEE ; Jae Hyung CHOI
Yeungnam University Journal of Medicine 2017;34(1):132-136
Leiomyosarcoma (LMS) of the small intestine is a rare tumor, accounting for about 1% of all malignant mesenchymal lesions in the gastrointestinal tract. Since small bowel tumors are initially asymptomatic and nonspecific, delayed diagnosis and treatment are common. We found that a 44-year-old male patient who came in for lower abdominal pain had partial obstruction in the small bowel. Multiple ascites and ileal tumors involving peritoneal seeding were observed from his abdominal computed tomography. He was diagnosed as epithelioid LMS involving peritoneal transition after surgical resection, and the outpatient department has planned for a conservative therapy with observation. To the best of our knowledge, ileal epithelioid LMS accompanying a huge omental mass, with a size of 18 cm in dimension, and peritoneal seeding has not yet been reported in Korea. We report this rare case with literature review.
Abdominal Pain
;
Adult
;
Ascites
;
Delayed Diagnosis
;
Gastrointestinal Tract
;
Humans
;
Ileum
;
Intestine, Small
;
Korea
;
Leiomyosarcoma
;
Male
;
Outpatients
5.The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
Jin Ho SONG ; Hong Gyun WU ; Bhum Suk KEAM ; Jeong Hun HAH ; Yong Chan AHN ; Dongryul OH ; Jae Myoung NOH ; Hyo Jung PARK ; Chang Geol LEE ; Ki Chang KEUM ; Jihye CHA ; Kwan Ho CHO ; Sung Ho MOON ; Ji Yoon KIM ; Woong Ki CHUNG ; Young Taek OH ; Won Taek KIM ; Moon June CHO ; Chul Seung KAY ; Yeon Sil KIM
Cancer Research and Treatment 2016;48(3):917-927
PURPOSE: We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). MATERIALS AND METHODS: A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed. RESULTS: After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). CONCLUSION: This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.
Arm
;
Chemoradiotherapy
;
Compliance
;
Disease-Free Survival
;
Drug Therapy*
;
Humans
;
Induction Chemotherapy
;
Methods
;
Nasopharyngeal Neoplasms
;
Propensity Score*
;
Radiotherapy
;
Recurrence
;
Republic of Korea
;
Retrospective Studies*
;
Standard of Care
;
Treatment Outcome
6.Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non-small cell lung cancer patients.
Yunseon CHOI ; Ik Jae LEE ; Chang Young LEE ; Jae Ho CHO ; Won Hoon CHOI ; Hong In YOON ; Yun Han LEE ; Chang Geol LEE ; Ki Chang KEUM ; Kyung Young CHUNG ; Seok Jin HAAM ; Hyo Chae PAIK ; Kang Kyoo LEE ; Sun Rock MOON ; Jong Young LEE ; Kyung Ran PARK ; Young Suk KIM
Radiation Oncology Journal 2015;33(2):75-82
PURPOSE: We evaluated the prognostic significance of T3 subtypes and the role of adjuvant radiotherapy in patients with resected the American Joint Committee on Cancer stage IIB T3N0M0 non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: T3N0 NSCLC patients who underwent resection from January 1990 to October 2009 (n = 102) were enrolled and categorized into 6 subgroups according to the extent of invasion: parietal pleura chest wall invasion, mediastinal pleural invasion, diaphragm invasion, separated tumor nodules in the same lobe, endobronchial tumor <2 cm distal to the carina, and tumor-associated collapse. RESULTS: The median overall survival (OS) and disease-free survival (DFS) were 55.3 months and 51.2 months, respectively. In postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, respectively). Patients with endobronchial tumors within 2 cm of the carina also showed better OS and DFS than those in the other T3 subtypes (p = 0.018 and p = 0.016, respectively). However, adjuvant radiotherapy did not cause any improvement in survival (OS, p = 0.518 and DFS, p = 0.463, respectively). Only patients with mediastinal pleural invasion (n = 25) demonstrated improved OS and DFS after adjuvant radiotherapy (n = 18) (p = 0.012 and p = 0.040, respectively). CONCLUSION: The T3N0 NSCLC subtype that showed the most favorable prognosis is the one with endobronchial tumors within 2 cm of the carina. Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.
Carcinoma, Non-Small-Cell Lung*
;
Diaphragm
;
Disease-Free Survival
;
Humans
;
Joints
;
Pleura
;
Prognosis
;
Radiotherapy, Adjuvant*
;
Thoracic Wall
7.Patterns of care for patients with nasopharyngeal carcinoma (KROG 11-06) in South Korea.
Soo Yoon SUNG ; Min Kyu KANG ; Chul Seung KAY ; Ki Chang KEUM ; Sung Hwan KIM ; Yeon Sil KIM ; Won Taek KIM ; Ji Yoon KIM ; Jin Hee KIM ; Sung Ho MOON ; Yong Chan AHN ; Young Taek OH ; Hong Gyun WU ; Chang Geol LEE ; Woong Ki CHUNG ; Kwan Ho CHO ; Moon June CHO ; Jin Hwa CHOI
Radiation Oncology Journal 2015;33(3):188-197
PURPOSE: To investigate the patterns of care for patients with nasopharyngeal carcinoma (NPC) in South Korea. MATERIALS AND METHODS: A multi-institutional retrospective study was performed (Korean Radiation Oncology Group [KROG] 11-06) on a total of 1,445 patients from 15 institutions. RESULTS: Of the 1,445 patients, more than half were stages III (39.9%) and IV (35.8%). In addition to patterns of care, we also investigated trends over time with the periods 1988-1993, 1994-2002, and 2003-2011. The frequencies of magnetic resonance imaging and positron emission tomography-computed tomography were markedly increased in the third period compared to previous 2 periods. Concurrent chemoradiation (CCRT) was performed on 894 patients (61.9%), neoadjuvant chemotherapy on 468 patients (32.4%), and adjuvant chemotherapy on 366 patients (25.3%). Of stage II-IV patients, CCRT performed on 78.8% in 2003-2011 compared to 15.0% in 1988-1993. For patients treated with CCRT, cisplatin was the most commonly used agent in 81.3% of patients. Over the periods of time, commonly used radiotherapy (RT) techniques were changed from 2-dimensional RT (1988-1993, 92.5%) to 3-dimensional RT (2003-2011, 35.5%) or intensity-modulated RT (IMRT; 2003-2011, 56.5%). Median RT doses given to primary tumors, high-risk lymphatics, and low-risk lymphatics were 70.0 Gy, 58.1 Gy, and 48.0 Gy, respectively. Adoption of IMRT increased the dose per fraction and escalated total radiation dose. CONCLUSION: Assessment of the patterns of care for NPC patients in South Korea demonstrated that management for NPC including diagnostic imaging, treatment regimen, RT techniques and dose schedule, advanced in accordance with the international guidelines.
Appointments and Schedules
;
Chemotherapy, Adjuvant
;
Cisplatin
;
Diagnostic Imaging
;
Drug Therapy
;
Electrons
;
Humans
;
Korea*
;
Magnetic Resonance Imaging
;
Nasopharyngeal Neoplasms
;
Radiation Oncology
;
Radiotherapy
;
Retrospective Studies
8.The anti-inflammatory effect of Cheongseoikki-tang ethanol extract on allergic reactions mediated by bone marrow-derived mast cells.
Joon-Ho KEUM ; Ok-Hwa KANG ; Sung-Bae KIM ; Su-Hyun MUN ; Yun-Soo SEO ; Ma-Ryong KIM ; Jung-Rae RHO ; Young-Seob LEE ; Chung-Berm PARK ; Young-Guk KIM ; Yong-Il KIM ; Sin-Hee HAN ; Dong-Yeul KWON
Chinese journal of integrative medicine 2013;19(5):380-386
OBJECTIVECheongseoikki-tang (CIT, Korean), also called Qingshu Yiqi decoction () and Seisho-ekki-to (Japanese), is well known as an effective traditional combination of herbs for treating cardiovascular diseases. This study was to research its effects on bone marrow-derived mast cell (BMMC)-mediated allergy and inflammation mechanisms.
METHODSIn this study, the biological effect of Cheongseoikki-tang ethanol extract (CITE) was evaluated, focusing on its effects on the production of allergic mediators by phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore A23187 (A23187)-stimulated BMMCs. These allergic mediators included interleukin-6 (IL-6), prostaglandin D2 (PGD2), leukotriene C4 (LTC4), and β-hexosaminidase (β-hex).
RESULTSOur data revealed that CITE inhibited the production of IL-6, PGD2, LTC4, and β-hex induced by PMA plus A23187 (P<0.05).
CONCLUSIONThese findings indicate that CITE has the potential for use in the treatment of allergy.
Animals ; Anti-Inflammatory Agents ; pharmacology ; therapeutic use ; Bone Marrow Cells ; pathology ; Calcimycin ; pharmacology ; Cell Degranulation ; drug effects ; Cell Survival ; drug effects ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Hypersensitivity ; drug therapy ; pathology ; Interleukin-6 ; secretion ; Leukotriene C4 ; pharmacology ; Male ; Mast Cells ; drug effects ; pathology ; physiology ; Mice ; Mice, Inbred BALB C ; Prostaglandin D2 ; biosynthesis ; Tetradecanoylphorbol Acetate ; pharmacology ; beta-N-Acetylhexosaminidases ; metabolism
9.The Efficacy of the Change in Belly Board Aperture Location by the Addition of Bladder Compression Device for Radiotherapy of Rectal Cancer.
Hong In YOON ; Yoonsun CHUNG ; Joo Ho KIM ; Hyo Kuk PARK ; Sang Kyu LEE ; Young Suk KIM ; Yunseon CHOI ; Misun KIM ; Hayoon LEE ; Jeesuk CHANG ; Hyejung CHA ; Jinsil SEONG ; Ki Chang KEUM ; Woong Sub KOOM
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2010;28(4):231-237
PURPOSE: We investigated the effect of location changes in the inferior border of the belly board (BB) aperture by adding a bladder compression device (BCD). MATERIALS AND METHODS: We respectively reviewed data from 10 rectal cancer patients with a median age 64 years (range, 45~75) and who underwent computed tomography (CT) simulation with the use of BB to receive pelvic radiotherapy between May and September 2010. A CT simulation was again performed with the addition of BCD since small bowel (SB) within the irradiated volume limited boost irradiation of 5.4 Gy using the cone down technique after 45 Gy. The addition of BCD made the inferior border of BB move from symphysis pubis to the lumbosacral junction (LSJ). RESULTS: Following the addition of BCD, the irradiated volumes of SB and the abdominopelvic cavity (APC) significantly decreased (174.3+/-89.5 mL vs. 373.3+/-145.0 mL, p=0.001, 1282.6+/-218.7 mL vs. 1571.9+/-158 mL, p<0.001, respectively). Bladder volume within the treated volume increased with BCD (222.9+/-117.9 mL vs. 153.7+/-95.5 mL, p<0.001). The ratio of irradiated bladder volume to APC volume with BCD (33.5+/-14.7%) increased considerably compared to patients without a BCD (27.5+/-13.1%) (p<0.001), and the ratio of irradiated SB to APC volume decreased significantly with BCD (13.9+/-7.6% vs. 24.2+/-10.2%, p<0.001). The ratios of the irradiated SB volumeand irradiated bladder volume to APC volume negatively correlated (p=0.001). CONCLUSION: This study demonstrated that the addition of BCD, which made the inferior border of BB move up to the LSJ, increased the ratio of the bladder to APC volume and as a result, decreased the irradiated volume of SB.
Humans
;
Rectal Neoplasms
;
Urinary Bladder
10.Correlation of the Nuclear beta-catenin Expression with the Clinicopathological Parameters of Hepatocellular Carcinoma.
Hyoung Jong KWAK ; Ha Na CHOI ; Sung Ho HWANG ; Keum Ha CHOI ; Ho Sung PARK ; Kyu Yun JANG ; Myoung Ja CHUNG ; Myoung Jae KANG ; Dong Geun LEE ; Woo Sung MOON
Korean Journal of Pathology 2008;42(4):208-214
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the human liver. However, the molecular changes and mechanisms that regulate the development and progression of HCC remain unclear. Beta-catenin is known as a multi-functional protein that acts as a regulator of the cadherin-mediated cell-cell adhesion system and also in the Wingless/Wnt signal transduction pathway. The aim of this study was to investigate the expression of beta-catenin and its possible role in HCC. METHODS: We investigated the expression of beta-catenin, Ki-67, TP53, alpha-smooth muscle actin and CD34 by performing immunohistochemical staining for 61 specimens of HCC and their adjacent non-tumorous tissue. We also examined the relationship between the nuclear expression of beta-catenin and the clinicopathologic parameters. RESULTS: The altered expression of beta-catenin was not detected in the nontumorous liver tissue. The nuclear expression of beta-catenin was observed in approximately 16% (10/61) of the HCC specimens. Double immunohistochemical staining for beta-catenin and E-cadherin showed a close relationship between nuclear translocation of beta-catenin and the loss of the membranous E-cadherin expression. Significant correlation was found between the nuclear translocation of beta-catenin and the tumor size, tumor necrosis and the presence of microvessel invasion and intrahepatic metastasis (p<0.05). CONCLUSIONS: This data indicates that nuclear translocation of beta-catenin could play a role in the growth and progression of HCC.
Humans
;
Carcinoma, Hepatocellular
;
Neoplasm Metastasis

Result Analysis
Print
Save
E-mail